Lazar David E. — SEC Form 4 filings
SEC reporting owner CIK 1932843. 28 Form 4 filings on record with FilingPulse; latest filed 2026-09-11.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2024-01-24 to 2026-09-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,456,980 shares, $49,974 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 3 filings — 195,737,388 shares, $5,591,426 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 46.
- Largest priced transaction: sale of 194,628,820 shares @ $0.03 ($5,507,996) in Cyclacel Pharmaceuticals, Inc., filed 2025-02-28.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. (CYCC) | 10% owner | 3 | — | 2 legs · 194,635,570 sh · $5,591,426 | 5 |
| FiEE, Inc. (MINM) | Director, 10% owner | 5 | 1 leg · 1,456,980 sh · $49,974 | — | 7 |
| LQR House Inc. (LQR) | President, Director | 2 | — | 2 legs · 1,101,818 sh | 1 |
| Quantum Cyber N.V. (QUCY) | Chief Executive Officer, Director, 10% owner | 3 | — | — | 13 |
| OPGEN INC (OPGN) | Chief Executive Officer, Director, 10% owner | 6 | — | — | 6 |
| Aterian, Inc. (ATER) | Chief Executive Officer, Director, 10% owner | 2 | — | — | 4 |
| NovaBay Pharmaceuticals, Inc. (NBY) | 10% owner | 2 | — | — | 3 |
| Sow Good Inc. (SOWG) | Director | 2 | — | — | 3 |
| Indaptus Therapeutics, Inc. (INDP) | Director | 1 | — | — | 2 |
| KALA BIO, Inc. (KALA) | Chief Executive Officer, Director | 2 | — | — | 2 |
Form 4 filings — Lazar David E.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Aterian, Inc. (ATER) | Conversion (C): 875,000 @ $2 · Grant/award (A): 1,750,000 (derivative) @ $2 · Conversion (C): 875,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Quantum Cyber N.V. (QUCY) | Conversion (C): 9,000,000 @ $9 · Conversion (C): 9,000,000 @ $9 · Conversion (C): 9,000,000 @ $9 · Conversion (C): 28,057,500 @ $225 · Conversion (C): 1,000,000 (derivative) @ $0 · Conversion (C): 1,000,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-05-01 | 4 | Aterian, Inc. (ATER) | Grant/award (A): 1,750,000 (derivative) | EDGAR |
| 2026-04-28 | 4 | Quantum Cyber N.V. (MYNZ) | Grant/award (A): 1,000,000 (derivative) @ $1.50 · Grant/award (A): 1,000,000 (derivative) @ $1.50 | EDGAR |
| 2026-04-02 | 4 | Sow Good Inc. (SOWG) | Grant/award (A): 5,740,000 @ $0.14 · Option exercise (M): 410,000 (derivative) @ $2 | EDGAR |
| 2026-03-24 | 4 | Indaptus Therapeutics, Inc. (INDP) | Sale (S): 196,800 (derivative) · Sale (S): 700,000 (derivative) | EDGAR |
| 2026-03-03 | 4 | MAINZ BIOMED N.V. (MYNZ) | Grant/award (A): 1,000,000 (derivative) · Grant/award (A): 1,000,000 (derivative) · Grant/award (A): 1,000,000 (derivative) | EDGAR |
| 2026-01-29 | 4 | NovaBay Pharmaceuticals, Inc. (NBY) | Grant/award (A): 6,388,000 · Option exercise (M): 39,925 (derivative) | EDGAR |
| 2026-01-05 | 4 | Sow Good Inc. (SOWG) | Grant/award (A): 1,500,000 (derivative) @ $2 | EDGAR |
| 2025-12-22 | 4 | KALA BIO, Inc. (KALA) | Other (J): 368,614 (derivative) | EDGAR |
| 2025-11-26 | 4 | KALA BIO, Inc. (KALA) | Grant/award (A): 900,000 (derivative) | EDGAR |
| 2025-10-17 | 4 | NovaBay Pharmaceuticals, Inc. (NBY) | Sale (S): 441,325 (derivative) | EDGAR |
| 2025-08-04 | 4 | Cyclacel Pharmaceuticals, Inc. (CYCC) | Sale (S): 6,750 @ $12.36 | EDGAR |
| 2025-04-07 | 4 | LQR House Inc. (LQR) | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2025-03-10 | 4 | FiEE, Inc. (MINM) | Grant/award (A): 1,200,000 · Sale (S): 2,219,447 (derivative) · Sale (S): 2,800,000 (derivative) | EDGAR |
| 2025-02-28 | 4 | Cyclacel Pharmaceuticals, Inc. (CYCC) | Option exercise (M): 2,650,000 · Option exercise (M): 191,978,820 · Sale (S): 194,628,820 @ $0.03 · Option exercise (M): 1,000,000 (derivative) · Option exercise (M): 1,745,262 (derivative) | EDGAR |
| 2025-02-10 | 4 | Cyclacel Pharmaceuticals, Inc. (CYCC) | Grant/award (A): 2,100,000 (derivative) | EDGAR |
| 2024-12-31 | 4 | MINIM, INC. (MINM) | Purchase (P): 1,456,980 @ $0.03 | EDGAR |
| 2024-11-25 | 4 | LQR House Inc. (LQR) | Sale (S): 821,818 · Sale (S): 280,000 | EDGAR |
| 2024-10-22 | 4 | MINIM, INC. (MINM) | Grant/award (A): 305,357 (derivative) | EDGAR |
| 2024-08-01 | 4/A | OPGEN INC (OPGN) | Grant/award (A): 150,000 (derivative) @ $1 | EDGAR |
| 2024-08-01 | 4 | OPGEN INC (OPGN) | Sale (S): 550,000 (derivative) | EDGAR |
| 2024-07-31 | 4/A | OPGEN INC (OPGN) | Grant/award (A): 200,000 (derivative) @ $1 | EDGAR |
| 2024-04-25 | 4 | OPGEN INC (OPGN) | Purchase (P): 150,000 (derivative) @ $1 | EDGAR |
| 2024-04-12 | 4 | OPGEN INC (OPGN) | Grant/award (A): 100,000 | EDGAR |
| 2024-04-08 | 4 | OPGEN INC (OPGN) | Purchase (P): 200,000 (derivative) @ $1 | EDGAR |
| 2024-01-31 | 4 | MINIM, INC. (MINM) | Purchase (P): 2,000,000 (derivative) @ $1.40 · Purchase (P): 2,800,000 (derivative) @ $0 | EDGAR |
| 2024-01-24 | 4 | MINIM, INC. (MINM) | Grant/award (A): 25,000 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1932843 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →